BI Prepares For Regulatory Filings After Spevigo Successfully Prevents GPP Flares

In Phase IIb trial

 
• By Ayisha Sharma

The German firm’s Spevigo seems set to dominate the generalized pustular psoriasis market after it reduced the risk of flares in the pivotal EFFISAYIL 2 trial, triggering label expansion plans less than a year after it was approved for flare treatment.  

Blocks with drawn outlines of different organs on them
GPP Flares Can Lead To Sepsis, Shock And Organ Failure • Source: Shutterstock

More from Clinical Trials

More from R&D